Addex to Present at the Swiss Equities Baader Conference

Company Overview - Addex Therapeutics is a clinical-stage pharmaceutical company focused on developing and commercializing allosteric modulators for neurological disorders [2] - The company’s lead drug candidate, ADX71149, is a positive allosteric modulator in Phase 2 clinical trials for epilepsy [2] - Addex is also advancing a preclinical pipeline targeting various neurological conditions, including chronic cough, stress-related disorders, schizophrenia, and mild neurocognitive disorders [2] Recent Developments - Dr. Robert Lütjens, Head of Discovery - Biology, will present a corporate update and discuss advances in Addex's CNS pipeline at the Swiss Equities Baader Conference from January 10-12, 2024 [1] - The presentation is scheduled for January 11, 2024, at 16:20 CET in Bad Ragaz, Switzerland [1] Collaboration and Licensing - Indivior PLC has licensed Addex's GABAB PAM program for developing drug candidates focused on substance use disorder [2] - The collaboration with Janssen Pharmaceuticals for ADX71149 highlights Addex's strategic partnerships in drug development [2]